JAK Inhibitor Therapy for Inflammation-Linked Resistant Depression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for depression and treatment-resistant depression (TRD) are ineffective for many patients, and there is a need for improved therapies due to the association of these conditions with inflammation markers in the blood and brain.

Innovation Solution

Administering an effective amount of a Janus kinase (JAK) inhibitor, such as baricitinib, to patients with depression or TRD to target inflammation-associated symptoms and pathways.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antidepressants are administered to patients with treatment-resistant depression, then some patients may experience temporary improvement, but the treatment ultimately fails to provide sustained relief and patients continue to exhibit depressive symptoms

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtime without sustained improvement

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent changes the therapeutic parameter from conventional antidepressants targeting neurotransmitter reuptake to JAK inhibitors targeting inflammatory pathways. This parameter change addresses treatment-resistant depression by addressing the underlying inflammatory mechanism rather than continuing with ineffective neurotransmitter-based treatments, thereby improving reliability and reducing time loss.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces JAK inhibitors as an intermediary substance that blocks the inflammatory pathway (JAK-STAT signaling) which is identified as the mediator between inflammation and depressive symptoms. This intermediary approach provides a new mechanism of action for patients who have exhausted conventional treatment options.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If multiple antidepressant treatments are attempted in sequence, then patients may eventually find some relief, but the cumulative time and treatment failures increase without guarantee of sustained improvement

Engineering Contradiction:

Improvetreatment optionsVSAvoidcumulative treatment time

Core Design Contradiction:

Adaptability or versatilityVSLoss of time

Solution Approach 1:

The patent positions JAK inhibitors as a universal treatment approach that can address multiple aspects of treatment-resistant depression simultaneously (inflammation, neurotransmitter dysfunction, and associated symptoms like fatigue and cognitive impairment). This multi-functional approach reduces the need for sequential trials of different antidepressant classes.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent fundamentally changes the treatment parameter from neurotransmitter modulation to anti-inflammatory therapy, providing a new dimension of treatment versatility for patients who have failed conventional antidepressants, thereby reducing cumulative treatment time without compromising adaptability.

Inventive Principle:

Principle #35Parameter changes

3Duration of action of stationary object

If antidepressant treatment is continued in patients who do not respond, then the treatment regimen is maintained, but patient suffering persists and quality of life remains compromised

Engineering Contradiction:

Improvetreatment durationVSAvoidpatient suffering

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of chronic inflammation (which causes patient suffering) into a therapeutic target. By using JAK inhibitors to block the inflammatory pathway, the treatment transforms the underlying cause of suffering into the mechanism of relief, providing benefit where conventional treatments have failed.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent applies preliminary anti-inflammatory action before depressive symptoms can fully manifest or worsen. By blocking the JAK-STAT inflammatory pathway early, the treatment prevents the cascade of events that lead to neurotransmitter dysfunction and severe depressive episodes, thereby reducing patient suffering while maintaining appropriate treatment duration.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20250360136A1Treatment or Reversal of Treatment Resistant Depression and Related Central Nervous System (CNS) Inflammatory Conditions with a JAK Inhibitor

Publication Date: 2025.11.27 EMORY UNIVERSITY

AI summary

This disclosure relates to methods of treating, preventing, or reversing inflammation-associated central nervous system (CNS) disorders or conditions comprising administering an effective amount of a Janus kinases (JAK) inhibitor such as baricitinib to a patient in need thereof. In certain embodiments, the CNS associated inflammatory disorder is depression, treatment resistant depression, fatigue, or cognitive dysfunction.